Rivkees is a Professor of the Practice of Health Services, Policy, and Practice in the School of Public Health. He served as Florida's State Surgeon General and Secretary of Health from 2019 to 2021. Before moving to Florida, he served as a professor of pediatrics with tenure at Yale University. Dr. Rivkees has had more than 35 years of continuous research funding from the National Institutes of Health. He was responsible for the safety alert on liver toxicity caused by the antithyroid drug propylthiouracil. This led to major international treatment practice changes.

Emanuel Goldman graduated with honors from the Bronx High School of Science in 1962, received a B.A. cum laude from Brandeis University in 1966, where he was a chemistry major, and he completed his Ph.D. in Biochemistry at M.I.T. in 1972. He did postdoctoral research at Harvard Medical School and at the University of California, Irvine, before joining the faculty of New Jersey Medical School in 1979, where he rose through the ranks to Professor in 1993. Among his awards and honors, he was a Damon Runyon Fellow, A Lievre Senior Fellow of the California Division- American Cancer Society, and a recipient of a Research Career Development Award from the National Cancer Institute. Among his service activities, he was an officer and organizer of the NY-NJ Molecular Biology Club, served as a full member of an American Cancer Society Study Section, and continues to serve on the editorial boards of "Protein Expression and Purification", and "Applied and Environmental Microbiology". He was also twice elected by his colleagues to serve as President of the university chapter of the American Association of University Professors, and he was elected to serve as Vice President and subsequently President of the Faculty Organization of NJMS. He published a Comment in the Lancet in July 2020 that began the process of reversing the mistaken belief that COVID-19 was transmitted from surfaces.

Vivek Gupta is an Associate Professor, and Associate Dean of Graduate Education & Research at St. John’s University College of Pharmacy. Dr Gupta is an experienced pharmaceutical researcher with an interest in developing novel therapies for respiratory disorders. His expertise lies in the fields of novel drug discovery and repurposing, and non-invasive delivery of small and macromolecules via inhalation route. He also has significant research interest in the fields of pharmaceutical scalability, and nano-repurposing. Dr. Gupta’s research group has published >75 high-impact studies in peer-reviewed journals. Dr. Gupta also serves on editorial boards of many peer-reviewed journals; and is also involved in national pharmaceutical organizations including AAPS and CRS. Multiple technologies and therapies developed by Dr. Gupta’s group have been patented and have been licensed to biotech start-ups including PulmoSIM Therapeutics.